JPS58159425A - Gel base - Google Patents

Gel base

Info

Publication number
JPS58159425A
JPS58159425A JP4385782A JP4385782A JPS58159425A JP S58159425 A JPS58159425 A JP S58159425A JP 4385782 A JP4385782 A JP 4385782A JP 4385782 A JP4385782 A JP 4385782A JP S58159425 A JPS58159425 A JP S58159425A
Authority
JP
Japan
Prior art keywords
gel base
fatty acid
ethyl cellulose
triglyceride
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4385782A
Other languages
Japanese (ja)
Inventor
Yoshio Ueda
上田 芳雄
Takehisa Hata
秦 武久
Jiro Fujisaki
藤崎 二郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to JP4385782A priority Critical patent/JPS58159425A/en
Publication of JPS58159425A publication Critical patent/JPS58159425A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:A gel base, containing ethyl cellulose in triglyceride of a medium fatty acid, and having a large variation in viscosity with temperature difference and improved operability in filling in a capsule. CONSTITUTION:A gel base obtained by adding 3-10pts.wt., preferably 5- 10pts.wt., ethyl cellulose to 100pts.wt. triglyceride of 6-10C fatty acid, e.g. caproic acid or caprylic acid. Preferably both are mixed under stirring and warming. The resultant gel base is heated and made to flow, and a drug is added thereto and mixed therewith under stirring. The resultant pharmaceutical composition is filled in a capsule and allowed to stand at ordinary temperature to gelatinize the contents to afford a soft or hard capsule.

Description

【発明の詳細な説明】 この発明は常温でゲルレイける基剤に関するものであり
、さらに詳細には中鎖脂肪酸トリグリセライドにエチル
セルロースを添加してなるゲル基剤に関するものである
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a base that can be gelled at room temperature, and more particularly to a gel base made by adding ethyl cellulose to medium-chain fatty acid triglyceride.

油性の薬物を軟カプセル剤あるいは硬カプセル剤とする
に際して、該油性薬物を脂肪酸トリグリセライドに溶解
して充填する方法が知られている。
When preparing oil-based drugs into soft capsules or hard capsules, a method is known in which the oil-based drug is dissolved in fatty acid triglyceride and then filled.

そして、該脂肪酸Yリグリセライドに無水ケイ酸マグネ
シウム、ステアリン酸アルミニウム等のゲル化剤を添加
することにより、油性薬物と脂肪酸トリクリセライトか
らなる医薬組成物をカプセル内でゲル化させる方法も知
られている。
A method is also known in which a pharmaceutical composition consisting of an oil-based drug and fatty acid tricrycerite is gelled in a capsule by adding a gelling agent such as anhydrous magnesium silicate or aluminum stearate to the fatty acid Y liglyceride. ing.

しかしながら、従来のゲル化剤では温度差による基剤自
体の粘度変化が小さいためカブセ)vへの充填時の作業
性に難点があった。
However, with conventional gelling agents, the viscosity of the base itself changes little due to temperature differences, so there was a problem in workability when filling the gelling agent into the container.

この発明の発明者らは、従来の基剤の難点を解消すべく
鋭意研究の結果、中鎖脂肪酸トリグリセライドにエチル
セルロースを添加すれば温度差による粘度の変動が大き
いゲル基剤が得られることを見出し、この発明を完成し
た。
The inventors of this invention conducted intensive research to resolve the drawbacks of conventional base materials, and discovered that by adding ethyl cellulose to medium-chain fatty acid triglyceride, a gel base whose viscosity fluctuates greatly due to temperature differences can be obtained. , completed this invention.

この発明のゲル基剤は中鎖脂肪酸トリグリセライドにエ
チルセルロースを添加した組成物からなる。中鎖脂肪酸
トリグリセライドとしては、炭素数6〜10の脂肪酸の
トリグリセフィトが含まれ、具体的にはカプロン酸トリ
グリセライド、カプリル酸トリグリセライド、カプリン
酸トリグリセライドなどが例示される。なお、これらの
トリグリセライドとモノグリセライドあるいはジグリセ
ライドどの混合物もこの発明の中鎖脂肪酸トリクリセラ
イトに含まれる。。
The gel base of this invention consists of a composition in which ethyl cellulose is added to medium chain fatty acid triglyceride. Medium-chain fatty acid triglycerides include triglycephytes of fatty acids having 6 to 10 carbon atoms, and specific examples include caproic acid triglyceride, caprylic acid triglyceride, and capric acid triglyceride. Incidentally, any mixture of these triglycerides and monoglycerides or diglycerides is included in the medium-chain fatty acid tricrycerite of the present invention. .

中鎖脂肪酸トリクリセライトに添加されるエチルセルロ
ースの添加割合は、中鎖脂肪酸トリクリセライド100
市危部に対して通常3〜10重量部であ飄好捷しくけ5
〜10重量部である。
The addition ratio of ethyl cellulose added to medium chain fatty acid tricryceride is 100% medium chain fatty acid tricryceride.
Usually 3 to 10 parts by weight is added to the city.
~10 parts by weight.

中鎖脂1l−7j酸トリクリセライトにエチルセルロー
スを添加するには、両者を室温で攪拌混合するだけでも
よいが、加濡丁に両者を攪拌混合すると好都合である。
In order to add ethyl cellulose to the medium chain fat 1l-7j acid tricrycerite, it is sufficient to simply stir and mix both at room temperature, but it is convenient to stir and mix both in a wet knife.

このようにして得られる基剤への薬物の混合は、通常加
温により流動化された基剤に薬物を加えて攪拌混合する
ことにより行われる。
Mixing of the drug into the base thus obtained is usually carried out by adding the drug to the base fluidized by heating and stirring and mixing.

このようにして得られる医薬組成物を軟カプセル剤ある
いは硬カプセル剤とする場合のカプセルへの充填は常法
により行われる。医薬組成物の充填されたカプセルは常
温で静置するだけで内容物がゲル化するが、冷却してゲ
ル化を促進してもよい。
When the pharmaceutical composition thus obtained is made into soft capsules or hard capsules, filling of the capsules is carried out by a conventional method. The contents of a capsule filled with a pharmaceutical composition will gel simply by standing at room temperature, but gelation may be promoted by cooling.

この発明のゲ/I/f5剤では、温度差による基剤の粘
度の変動が大きいためカプセル充填時の作業性に好まし
い結果をもたらす。その上、このゲル基剤にビタミンE
、クロタミトン等の油性薬物を添加すると、予期に反し
て透明となる。したがって、この発明のゲル基剤を用い
ると、外観のすぐれた医薬組成物が得られ、かつ目視に
より異種薬物の混入を容易に発見できる々と、すぐれた
効果を奏せる。
In the Ge/I/f5 agent of the present invention, the viscosity of the base material fluctuates greatly due to temperature differences, which brings about favorable results in terms of workability during capsule filling. Moreover, this gel base contains vitamin E.
When an oil-based drug such as crotamiton is added, it unexpectedly becomes transparent. Therefore, when the gel base of the present invention is used, a pharmaceutical composition with an excellent appearance can be obtained, and contamination with a different type of drug can be easily detected by visual inspection, which is an excellent effect.

なお、この発明のゲル基剤を加温溶融し、これに薬物を
懸濁させたのちにゲル化してもよい。また、この発明の
ゲル基剤の用途が医薬用に限定されるものでないことは
勿論である。
Note that the gel base of the present invention may be heated and melted, a drug may be suspended therein, and then gelled. Furthermore, it goes without saying that the use of the gel base of the present invention is not limited to medical use.

試験例1 カプリル酸トリグリセライドとカプリン酸トリクリセラ
イトとの混合物(商品名:パナセート810、日本油脂
株式会社製)に対するエチルセルロースの添加割合を変
えた種々の基剤を製し、それぞれの基剤の40°Cにお
ける粘度を回転粘度計により測定した。結果を表1に示
す。なお、エチルセルロースの添加割合はパナセート8
10(商品名)100重量部に添加されたエチルセルロ
ースの重爪部で表示する。
Test Example 1 Various bases were prepared with different addition ratios of ethyl cellulose to a mixture of caprylic acid triglyceride and capric acid tricrycerite (trade name: Panacet 810, manufactured by NOF Corporation). The viscosity at °C was measured using a rotational viscometer. The results are shown in Table 1. In addition, the addition ratio of ethyl cellulose is Panacet 8
10 (trade name) It is expressed as the weight of ethyl cellulose added to 100 parts by weight.

試験例2 実施例1で得られた基剤(エチル士ルロース5%含イ〕
)の粘度を温度を変えて測定した。結果を表2に示す。
Test Example 2 Base obtained in Example 1 (containing 5% ethylylulose)
) was measured at different temperatures. The results are shown in Table 2.

表  2 次にこの発明を実施例により説明する。Table 2 Next, the present invention will be explained with reference to examples.

実施例1 カプリル酸トリグリセライドとカプリン酸トリグリセラ
イドの混合物(85:15)(95重量部)を40°C
に加温し、これにエチルセルロース(5重量部)を加え
て攪拌混合してゲル基剤を得る。
Example 1 A mixture of caprylic acid triglyceride and capric acid triglyceride (85:15) (95 parts by weight) was heated at 40°C.
Ethyl cellulose (5 parts by weight) was added thereto and mixed with stirring to obtain a gel base.

このゲル基剤(50重量部)を約80°Cに加熱し、こ
れにビタミンE(50重量部)を加えて攪拌混合して、
ビタミンEの組成物を得る。
This gel base (50 parts by weight) was heated to about 80°C, vitamin E (50 parts by weight) was added thereto, and the mixture was stirred.
A composition of vitamin E is obtained.

この組成物を約60°Cに加温し、常法により透明な硬
カプセルに注入充填する。これを室温で放置すると、ゲ
ル状の透明なビタミンE組成物を含有する硬カプセル剤
を得る。
This composition is heated to about 60°C and injected into transparent hard capsules in a conventional manner. When this is left at room temperature, hard capsules containing a gel-like transparent vitamin E composition are obtained.

実施例2 カプリル酸l・リグリセライドとカプリン酸トリクリセ
ライトの混合物(85:15)(97重量部)を40°
Cに加温し、これにエチルセルロース(6重量部)を加
えて攪拌混合してゲル基剤を得る。
Example 2 A mixture of caprylic acid liglyceride and capric acid tricrycerite (85:15) (97 parts by weight) was heated at 40°
C. Ethyl cellulose (6 parts by weight) is added thereto and mixed with stirring to obtain a gel base.

このゲル基剤(90爪量部)を約80°Cに加熱し、こ
れにクログミ1−ン(10屯呈部)を加えて攪拌混合し
て、クロタミトンの組成物を得る。
This gel base (90 parts) is heated to about 80 DEG C., and 10 parts of crotamiton is added thereto and mixed with stirring to obtain a composition of crotamiton.

と、ゲル状の透明なりロタミトン組成物を含有する軟カ
プセル剤を得る、。
and obtaining a soft capsule containing a transparent gel-like rotamiton composition.

特許出願人  藤沢薬品工業株式会社 7−Patent applicant: Fujisawa Pharmaceutical Co., Ltd. 7-

Claims (2)

【特許請求の範囲】[Claims] (1)中鎖脂肪酸トリグリセライドにエチルセルロース
を添加してなるゲ/1/基剤。
(1) Ge/1/base made by adding ethyl cellulose to medium chain fatty acid triglyceride.
(2)中鎖脂肪酸トリグリセライドがカプリル酸トリグ
リセライドとカプリン酸トリグリセライドとの混合物で
ある特許請求の範囲第1項記載のゲル基剤。
(2) The gel base according to claim 1, wherein the medium chain fatty acid triglyceride is a mixture of caprylic triglyceride and capric triglyceride.
JP4385782A 1982-03-18 1982-03-18 Gel base Pending JPS58159425A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4385782A JPS58159425A (en) 1982-03-18 1982-03-18 Gel base

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4385782A JPS58159425A (en) 1982-03-18 1982-03-18 Gel base

Publications (1)

Publication Number Publication Date
JPS58159425A true JPS58159425A (en) 1983-09-21

Family

ID=12675372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4385782A Pending JPS58159425A (en) 1982-03-18 1982-03-18 Gel base

Country Status (1)

Country Link
JP (1) JPS58159425A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5257357A (en) * 1975-08-18 1977-05-11 Procter & Gamble Gelatinized fatty particle
JPS54147914A (en) * 1978-04-25 1979-11-19 Pharmaceutical Licences Co Stabilizing method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5257357A (en) * 1975-08-18 1977-05-11 Procter & Gamble Gelatinized fatty particle
JPS54147914A (en) * 1978-04-25 1979-11-19 Pharmaceutical Licences Co Stabilizing method

Similar Documents

Publication Publication Date Title
CA2159580C (en) Pharmaceutical compositions containing polyvinylpyrrolidone and a tri-ester and process of manufacture thereof
JP4990474B2 (en) Process for the preparation of pharmaceutical compositions for use with soft gelatin formulations
RU1800996C (en) Method for capsule producing
JPS62114911A (en) Oral administration type slow release medicine
JP5005339B2 (en) Alpha-hydroxy acid ester drug delivery compositions and methods of use
EP0103995B1 (en) Medicated suppository
ES2197647T3 (en) TIXOTROPIC FORMULATIONS FOR THE FILLING OF CAPSULES.
JPS6067416A (en) Gel or gel-containing composition and manufacture
JP2001031565A (en) Capsule preparation containing loxoprofen sodium
JPS58159425A (en) Gel base
JPS63198618A (en) Encapsulation
JPH0364483B2 (en)
JPS634524B2 (en)
JPS58206515A (en) Hard capsule preparation
JPH03128322A (en) Pharmaceutical composition containing polyprenyl compound and its production
ES2313235T3 (en) HARD GELATINE CAPSULE THAT PRESENTS AN IMPROVED FILM RESISTANCE.
JPH10330250A (en) Menatetrenone oily formulation
JPH05507717A (en) Amantadine hydrochloride suspension with enhanced dissolution properties for use in soft gelatin capsules
JPS6054313A (en) Heparin composition absorbable through intestine
BRPI0212299B1 (en) oily thixotropic vehicle, its preparation process, filler, and pharmaceutical unit dose
JP3144865B2 (en) Soft capsule
JPH07549B2 (en) Composition for filling soft capsules
WO2004010994A1 (en) Indometacin preparation for external use
JPH1149667A (en) Hard gelatin capsule
JPS6364402B2 (en)